Phreesia, Inc. (PHR)

Phreesia, Inc. (PHR) is a leading Software-as-a-Service (SaaS) company that has successfully digitized the patient intake and payment process in the U.S. healthcare system. Led by CEO Chaim Indig, Phreesia’s strategic mission is to "create a better experience for patients, providers, and staff by automating the healthcare journey." The company holds a dominant industry position, facilitating more than 170 million patient visits annually—roughly one in seven visits across the United States. The company’s vision is to ensure that "every person is an active participant in their care." In late 2025, PHR stock reached a major financial milestone, swinging from an Adjusted EBITDA loss to a positive $36.8 million, signaling a permanent shift toward profitability. The PHR stock price has been further bolstered by the company’s inclusion in TIME’s 2025 List of the World’s Top HealthTech Companies.

The business operations of Phreesia are centered on its proprietary platform, which manages patient access, registration, clinical support, and payments. In fiscal 2025, total revenue grew by 18% to $419.8 million. A primary growth driver is the "Network Solutions" segment, which connects life sciences companies and health systems with patients at the point of care; this segment saw 25% year-over-year growth in 2025. The 2026 strategic roadmap focuses on "Inorganic Expansion," highlighted by the November 2025 acquisition of AccessOne, which enhances Phreesia’s patient financing and payment capabilities. Phreesia holds an "Interoperability Moat," as its deep integration with over 80 electronic health record (EHR) systems makes it a mission-critical component of medical office workflows. With an Average Healthcare Services Client (AHSC) count of over 4,400, the company is effectively the "digital front door" for much of the American medical establishment, making PHR stock a strategic play on the modernization of healthcare infrastructure.

Phreesia, Inc. (PHR) is listed on the New York Stock Exchange (NYSE). Investors monitoring PHR stock have praised the company’s operating leverage, as it achieved a $72 million improvement in operating performance in a single fiscal year. The PHR stock price is highly responsive to growth in AHSCs and "Payment Volume," which exceeded $4 billion in 2025. For those researching PHR stock, the company’s transition to positive free cash flow and its role in reducing administrative friction in a $4 trillion healthcare market provide a compelling long-term investment case. The PHR stock remains a top pick for growth-oriented healthcare technology portfolios.